Sorry I don't know why that link didn't work. I'm not sure of the person you mention, as this was the bio of the Ceo previous to the current.
"Mr. Daniel M. Junius, also known as Dan, served as the Chief Executive Officer of ImmunoGen, Inc. from January 01, 2009 to May 13, 2016 and served as its President from July 2008 to May 13, 2016. Mr. Junius has over two decades of experience in financial management and business strategy, including nearly ten years as Chief Financial Officer at two NYSE-listed companies. He served as an Acting Chief Financial Officer of ImmunoGen, Inc. from September 13, 2013 to December 30, 2013. He joined ImmunoGen, Inc. in May 2005 and served as its Acting Chief Financial Officer from July 2008 to January 2009, Executive Vice President from July 2006 to July 2008, Treasurer until July 2008, Principal Accounting Officer from May 2006 to July 2008, Executive Vice President of Finance since July 2006, Senior Vice President of Finance since May 9, 2005, Chief Operating Officer from July 2008 to January 2, 2009 and Chief Financial Officer from May 9, 2005 to July 2008. He has twenty years of business experience. He served as the Chief Financial Officer and Treasurer at New England Business Service, Inc. since 1998 and also served as its Executive Vice President since August 1, 2002. He served as the Chief Financial Officer and Treasurer of Deluxepinpoint from 1998 to 2004 and its Executive Vice President from August 1, 2002 to 2004. He joined DELUXEPINPOINT in 1998. He served as Chief Financial Officer of Nashua Corporation from 1996 to 1998, Vice President of Finance from 1995 to 1998 and its Treasurer since 1985. He joined Nashua Corporation in 1984 and served financial management positions of increasing responsibility. He has been an Independent Director of IDEXX Laboratories, Inc. since March 11, 2014 and Cerion Technologies Inc. Liquidating Trust since January 1996. He has been a Director of GlycoMimetics, Inc. since March 21, 2016. He has been a Director of ImmunGgen, Inc. since November 2008. He served as a Director of Vitae Pharmaceuticals, Inc. from July 27, 2016 to October 25, 2016. He served as a Director of IDEXX Laboratories, Inc. since July 2008. Mr. Junius holds Bachelor of Arts in Political Science from Boston College and Master's in Management from Northwestern University's Kellogg School of Management"
In your zest to explain the attributes of the company, I think you entirely missed my point. This CEO had brought this company to a certain level, but couldn't get them to the next. A severely eroding stock price most likely brought the change to fruition. A CEO with experience has taken the helm and is turning this stock back in the right direction. Given shareholders some confidence in direction, hopes etc of this company.
Our company has been promising partnerships for as long as I can remember. UT was a start so I though. But when their trial was basically moving slower than slow, doubts started. And then the hammer came down. Gone for reasons we will never know. Since then, nada. At least nowhere near the level of UT.
There is no shame in realizing that you are over your head. Again, with the millions of shares they own, why not put this in more capable hands. Heck even the board would want this with their average of approximately half a million shares.
But no, wouldn't have that happen. Instead promote someone with even less experience to join in steering the ship. Why would anyone with the so called business experience allow this to happen? Either one of two things IMO. Realization they are over their heads, and wanting to try and get help from someone they have worked with for many years. Or just wanting to let this long time business acquaintance of many years, reap the benefits of being the co-CEO.
No breaking up the company into two divisions. No nothing. Just a promotion, eating more of our valuable cash, for reasons I have never seen anyone try to defend. Honestly EichKing's statement on not wanting experienced people in there to see the many faults of this company, could be a real possibility.
Looking at the bios of both Sangamo, and Immunogen, among others, brings about a true sense of dismay when thinking about to incredible potential this company has. Many other companies that are less advanced in their trials, have improved price and market cap dramatically. We sit stagnant year after year.
Pretty much the only explanation I can think of is the management team. Controller...LMBO. What do you think potential partners, large investors think when they meet with these guys? They have a hard enough time getting scripted interviews out without looking nervous or twitchy. How do you think they would fair in a large Pharma boardroom talking with people with decades of experience in the field.
Something's amiss here. If anyone has a better explanation of our stagnant price for many years please feel free. We were getting a closer and closer 52 week trading range. Down to close to within half a buck. If it weren't for the pump for the raise, we'd probably be close to with 30 to 40 cents. How many biotech stocks can you say that about. You'd even be hard pressed to find this tight a range as it stands even with the pump. Many have well over a 200% or even 500% range. We sit exactly at 100% thanks to the pump.
